Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?

Endocrine therapy (ET) has been underexplored in endometrial cancer. Emerging data suggest that combining ET with cyclin-dependent kinase 4/6 inhibitors improves outcomes in endometrial cancer. This commentary complements a recent CCR article and reviews the opportunities to improve precision ET and the potential to overcome resistance mechanisms associated with ET failure.

See related article by Green et al., p. XX